Safety of new biologic therapies in rheumatoid arthritis

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

The common side effects associated with the use of TNF inhibitors are mild, well tolerated, self-limiting, and seldom enough of a nuisance to warrant discontinuation. The benefit-to-risk ratio for the anticytokine therapies appears to be very favorable for patients with aggressive RA. Serious and potentially life threatening adverse events are rare, even in the postmarketing era. As many of these serious toxicities occur at rates of < 1 case per 1,000 patient years of TNF inhibitor use, it appears that proper patient selection and prevention measures may limit this risk further.

Original languageEnglish (US)
JournalBulletin on the Rheumatic Diseases
Volume52
Issue number8
StatePublished - Dec 1 2003
Externally publishedYes

Fingerprint

Biological Therapy
Rheumatoid Arthritis
Safety
Patient Selection
Odds Ratio
Therapeutics

ASJC Scopus subject areas

  • Rheumatology

Cite this

Safety of new biologic therapies in rheumatoid arthritis. / Cush, John J.

In: Bulletin on the Rheumatic Diseases, Vol. 52, No. 8, 01.12.2003.

Research output: Contribution to journalReview article

@article{3134d590c3cc4b6ca2fde3c8e517c8c1,
title = "Safety of new biologic therapies in rheumatoid arthritis",
abstract = "The common side effects associated with the use of TNF inhibitors are mild, well tolerated, self-limiting, and seldom enough of a nuisance to warrant discontinuation. The benefit-to-risk ratio for the anticytokine therapies appears to be very favorable for patients with aggressive RA. Serious and potentially life threatening adverse events are rare, even in the postmarketing era. As many of these serious toxicities occur at rates of < 1 case per 1,000 patient years of TNF inhibitor use, it appears that proper patient selection and prevention measures may limit this risk further.",
author = "Cush, {John J.}",
year = "2003",
month = "12",
day = "1",
language = "English (US)",
volume = "52",
journal = "Bulletin on the Rheumatic Diseases",
issn = "0007-5248",
number = "8",

}

TY - JOUR

T1 - Safety of new biologic therapies in rheumatoid arthritis

AU - Cush, John J.

PY - 2003/12/1

Y1 - 2003/12/1

N2 - The common side effects associated with the use of TNF inhibitors are mild, well tolerated, self-limiting, and seldom enough of a nuisance to warrant discontinuation. The benefit-to-risk ratio for the anticytokine therapies appears to be very favorable for patients with aggressive RA. Serious and potentially life threatening adverse events are rare, even in the postmarketing era. As many of these serious toxicities occur at rates of < 1 case per 1,000 patient years of TNF inhibitor use, it appears that proper patient selection and prevention measures may limit this risk further.

AB - The common side effects associated with the use of TNF inhibitors are mild, well tolerated, self-limiting, and seldom enough of a nuisance to warrant discontinuation. The benefit-to-risk ratio for the anticytokine therapies appears to be very favorable for patients with aggressive RA. Serious and potentially life threatening adverse events are rare, even in the postmarketing era. As many of these serious toxicities occur at rates of < 1 case per 1,000 patient years of TNF inhibitor use, it appears that proper patient selection and prevention measures may limit this risk further.

UR - http://www.scopus.com/inward/record.url?scp=7044230795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7044230795&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:7044230795

VL - 52

JO - Bulletin on the Rheumatic Diseases

JF - Bulletin on the Rheumatic Diseases

SN - 0007-5248

IS - 8

ER -